©
Cyrus Mower
The Oxford-Harrington Rare Disease Cenre (OHC) unites world-leading research across the U.K. and U.S. with expertise in therapeutics development by combining University of Oxford’s scientific leadership and resources (250+ principal investigator scientists working on over 350 rare diseases) with Harrington Discovery Institute’s track record of advancing breakthrough medicines into clinical development (177 medicines funded, 36 companies launched, 19 medicines into the clinic, and 13 licenses to pharma companies since its founding in 2012).
The Accelerator is a first-in-kind, transatlantic initiative to identify, fund and advance breakthrough academic discoveries to deliver new treatments for the 400 million people worldwide who suffer from rare diseases. Its goal is to deliver 40 new potentially life-changing therapies for rare diseases into clinical trials over the next ten years and target multiple approvals from regulators in key markets including the U.S., the U.K. and Europe.
David Cameron, the former U.K. Prime Minister, who was present at the launch event, will lead the international efforts of the Accelerator under his role as Chair of the Oxford-Harrington Rare Disease Centre Advisory Board.